e-learning
resources
London 2016
Wednesday, 07.09.2016
The nature of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Anti-fibrotic effects of pirfenidone on pulmonary arterial vascular smooth muscle cells
Changwu Lu (Giessen, Germany), Changwu Lu, Tatyana Novoyatleva, Baktybek Kojonazarov, Hossein Ardeschir Ghofrani, Friedrich Grimminger, Norbert Weissmann, Werner Seeger, Ralph Schermuly
Source:
International Congress 2016 – The nature of pulmonary hypertension
Session:
The nature of pulmonary hypertension
Session type:
Poster Discussion
Number:
5091
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Changwu Lu (Giessen, Germany), Changwu Lu, Tatyana Novoyatleva, Baktybek Kojonazarov, Hossein Ardeschir Ghofrani, Friedrich Grimminger, Norbert Weissmann, Werner Seeger, Ralph Schermuly. Anti-fibrotic effects of pirfenidone on pulmonary arterial vascular smooth muscle cells. Eur Respir J 2016; 48: Suppl. 60, 5091
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Increased Cyr61 in pulmonary arterial hypertension involving in proliferation of pulmonary arterial smooth muscle cells
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
Source: Eur Respir J 2011; 37: 1104-1118
Year: 2011
IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Antiproliferative effects of drugs affecting different signalling pathways on rat and human pulmonary artery smooth muscle cells
Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH
Year: 2015
SMAD3 regulation contributes to lung vascular remodeling in pulmonary arterial hypertension
Source: International Congress 2015 – Respiratory translational research: novel mechanisms, diagnostic markers and Space Odyssey
Year: 2015
Smooth muscle microparticles as novel biomarkers of vascular remodelling and inflammation in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Nuclear factor-kappa B inhibition exerts anti-remodelling effects in pulmonary arterial smooth muscle cells
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014
Uric acid causes excessive pulmonary arterial smooth muscle cell proliferation via URATv1 upregulation in pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Imatinib lowers the pulmonary vascular tone in human and guinea pig lung tissue
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Pulmonary hypertension: the science behind the disease spectrum
Source: Eur Respir Rev 2012; 21: 19-26
Year: 2012
Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Obligatory role of MEK/ERK/RSK90 in the mitogenic responses of human pulmonary artery smooth muscle cells
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
MIF/CD74 contributes to the endothelial pro-inflammatory phenotype in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition
Source: Eur Respir J 2008; 31: 599-610
Year: 2008
NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Endothelial-derived MIF contributes to pulmonary endothelial cell proliferation in human pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
The effect of ASK1 inhibition on hypoxia-induced pulmonary artery fibroblast activation and associated paracrine effects on vascular smooth muscle cells
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept